ERBB2 and breast cancer: Thus, to further confirm the relation between miR-205, HER3 expression and sensitivity to Trastuzumab, we took advantage of HER2+ patient-derived BC xenografts (PDXs), which maintain the characteristics of the primary tumor (Supplementary Figure 3), and show different sensitivity to Trastuzumab (Figure 3A).